# Carolina Garrido Pavon

List of Publications by Year
in descending order



| 49 | 2,148 | 186265 | 233421 |
|---|---|---|---|
| papers | citations | 28 h-index | 45 g-index |

| 53 | 53 | 53 | 2953 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication. Nature Immunology, 2021, 22, 423-433. | 14.5 | 59 |
| 2 | Editorial: Immunotherapies Towards HIV Cure. Frontiers in Cellular and Infection Microbiology, 2021, 11, 655363. | 3.9 | 0 |
| 3 | SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science Immunology, 2021, 6, . | 11.9 | 34 |
| 4 | Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. JCI Insight, 2021, 6, . | 5.0 | 45 |
| 5 | Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. Scientific Reports, 2020, 10, 5134. | 3.3 | 32 |
| 6 | Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. Journal of Clinical Investigation, 2020, 130, 5157-5170. | 8.2 | 22 |
| 7 | Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation. PLoS Pathogens, 2020, 16, e1008954. | 4.7 | 22 |
| 8 | In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. Aids, 2019, 33, 605-613. | 2.2 | 21 |
| 9 | Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. Journal of Virology, 2018, 92, . | 3.4 | 96 |
| 10 | Î³Î´ T cells: an immunotherapeutic approach for HIV cure strategies. JCI Insight, 2018, 3, . | 5.0 | 27 |
| 11 | Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers. Virus Research, 2017, 228, 141-146. | 2.2 | 9 |
| 12 | HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Frontiers in Immunology, 2016, 7, 356. | 4.8 | 47 |
| 13 | Peripheral Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection. PLoS Pathogens, 2015, 11, e1005201. | 4.7 | 66 |
| 14 | Dual-Affinity Re-Targeting proteins direct T cellâ€“mediated cytolysis of latently HIV-infected cells. Journal of Clinical Investigation, 2015, 125, 4077-4090. | 8.2 | 124 |
| 15 | Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. Journal of Infectious Diseases, 2015, 212, 258-263. | 4.0 | 86 |
| 16 | Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. Molecular Therapy, 2015, 23, 387-395. | 8.2 | 46 |
| 17 | Gold nanoparticles to improve HIV drug delivery. Future Medicinal Chemistry, 2015, 7, 1097-1107. | 2.3 | 60 |
| 18 | Translational challenges in targeting latent HIV infection and the CNS reservoir problem. Journal of NeuroVirology, 2015, 21, 222-226. | 2.1 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nature Reviews Microbiology, 2014, 12, 750-764. | 28.6 | 247 |
| 20 | Antiviral effect of raltegravir on HTLV-1 carriers. Journal of Antimicrobial Chemotherapy, 2012, 67, 218-221. | 3.0 | 39 |
| 21 | Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. Antimicrobial Agents and Chemotherapy, 2012, 56, 2873-2878. | 3.2 | 62 |
| 22 | Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. AIDS Research and Human Retroviruses, 2012, 28, 156-164. | 1.1 | 18 |
| 23 | Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay. Journal of Clinical Microbiology, 2012, 50, 569-572. | 3.9 | 41 |
| 24 | Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. Aids, 2012, 26, 551-557. | 2.2 | 9 |
| 25 | Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68. | 2.0 | 7 |
| 26 | Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. Journal of Clinical Virology, 2011, 50, 148-152. | 3.1 | 9 |
| 27 | Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients â€“ Impact of HIV subtypes and prior raltegravir experience. Antiviral Research, 2011, 90, 164-167. | 4.1 | 48 |
| 28 | HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System. Journal of Antimicrobial Chemotherapy, 2011, 66, 260-264. | 3.0 | 14 |
| 29 | New therapeutic strategies for raltegravir. Journal of Antimicrobial Chemotherapy, 2010, 65, 218-223. | 3.0 | 11 |
| 30 | Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. Journal of Antimicrobial Chemotherapy, 2010, 65, 320-326. | 3.0 | 54 |
| 31 | High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. Journal of Antimicrobial Chemotherapy, 2010, 65, 1486-1492. | 3.0 | 63 |
| 32 | Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. AIDS Research and Human Retroviruses, 2009, 25, 967-972. | 1.1 | 14 |
| 33 | Dried Blood Spots Perform Well in Viral Load Monitoring of Patients Who Receive Antiretroviral Treatment in Rural Tanzania. Clinical Infectious Diseases, 2009, 49, 976-981. | 5.8 | 87 |
| 34 | Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. Journal of Clinical Microbiology, 2009, 47, 1031-1036. | 3.9 | 66 |
| 35 | Improvement in the determination of HIVâ€1 tropism using the V3 gene sequence and a combination of bioinformatic tools. Journal of Medical Virology, 2009, 81, 763-767. | 5.0 | 50 |
| 36 | Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. Journal of Clinical Virology, 2009, 46, 173-175. | 3.1 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Raltegravir and Etravirine Are Active against HIV Type 1 Group O. AIDS Research and Human Retroviruses, 2009, 25, 225-227. | 1.1 | 41 |
| 38 | Role of atazanavir in the treatment of HIV infection. Therapeutics and Clinical Risk Management, 2009, 5, 99-116. | 2.0 | 11 |
| 39 | Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. Journal of Antimicrobial Chemotherapy, 2008, 61, 694-698. | 3.0 | 53 |
| 40 | Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. Clinical Infectious Diseases, 2008, 46, 1782-1785. | 5.8 | 19 |
| 41 | HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4ÂC. Journal of Antimicrobial Chemotherapy, 2008, 61, 1217-1220. | 3.0 | 57 |
| 42 | Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. Journal of Clinical Microbiology, 2008, 46, 887-891. | 3.9 | 98 |
| 43 | Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 241-244. | 2.1 | 38 |
| 44 | Different disease progression rate according to HIV-1 subtype. Future HIV Therapy, 2008, 2, 319-322. | 0.4 | 2 |
| 45 | Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. Aids, 2008, 22, 311-313. | 2.2 | 8 |
| 46 | Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. AIDS Research and Human Retroviruses, 2007, 23, 879-885. | 1.1 | 35 |
| 47 | Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy, 2007, 60, 1409-1410. | 3.0 | 31 |
| 48 | High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. Aids, 2007, 21, 2503-2511. | 2.2 | 66 |
| 49 | Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure. Frontiers in Immunology, 0, 13, . | 4.8 | 2 |